PFAINasdaqAgricultural ServicesUS GAAP · USD

Pinnacle Food Group Ltd

Pinnacle Food Group Ltd is a United States-listed, technology-driven agricultural services company focused on smart agriculture and bio-engineering. Its business combines Farming-as-a-Service solutions with precision fermentation and synthetic biology platforms to develop sustainable food and biological ingredients.

Liikevaihto3,4milj. USD
+3,7 %v/v
Liikevoitto (EBIT)−1,9milj. USD
−412,6 %v/v
EBIT-marginaali−56,3%
−75,0 %-yks.v/v
Nettotulos−1,9milj. USD
−765,4 %v/v
Vapaa kassavirta−5,3milj. USD
−798,9 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2022–2025

−2024milj. USD2022: 0,18 milj. USD2022: EBIT −0,20 milj. USD20222023: 2,1 milj. USD2023: EBIT 1,0 milj. USD20232024: 3,3 milj. USD2024: EBIT 0,61 milj. USD20242025: 3,4 milj. USD2025: EBIT −1,9 milj. USD20253,4−1,9
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Farming-as-a-Service40 %

Technology-enabled agriculture services and solutions for efficient farm operations.

Precision Fermentation35 %

Fermentation-based development of food and ingredient outputs using engineered biology.

Synthetic Biology Platforms20 %

Research and production platforms for designing and scaling biological ingredients.

Research Collaboration and Licensing5 %

Partnerships, hub-based collaboration, and access to synthetic biology tools.

Tuotteet

Raportoitu · osuus liikevaihdosta
60,5%22,2%11,7%FY2025100 %
  • Recognized At Point of Time60,5 %
  • Construction Services22,2 %
  • Consulting Services11,7 %
  • Faa S Services5,5 %

Lähde: 20-F FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

The company appears to sell primarily to business customers in food, ingredient, and industrial biotechnology markets rather than to consumers. Its reported focus is on industry partners, research collaborators, and B2B manufacturers that need scalable biological inputs, fermentation capabilities, or smart agriculture solutions.

Food ingredient manufacturers

Buy high-value biological ingredients such as recombinant proteins for formulation and production.

Industrial biotechnology partners

Use the company's fermentation and synthetic biology capabilities to develop scalable bioproducts.

Agriculture operators

Use Farming-as-a-Service tools to improve efficiency, productivity, and sustainability.

Research and innovation partners

Collaborate on yeast research, open-source tools, and bio-engineering ecosystem development.

Strategia

The company’s stated strategy is to combine farming services with bio-engineering under a “Dual-Engine” model. It is prioritizing precision fermentation, synthetic biology, and partnership ecosystems to move toward commercial B2B biological ingredient supply.

Commercialize precision fermentation outputsLyhyt aikaväli

This is central to turning R&D milestones into scalable B2B product revenue.

Expand the B2B ingredient platformKeskipitkä aikaväli

A supplier model to manufacturers and partners can support broader adoption than standalone projects.

Build collaboration hubs and ecosystemsKeskipitkä aikaväli

Partnership access can improve distribution, research throughput, and market reach in Asia.

Maantiede

2025

Pinnacle Food Group is headquartered in Vancouver, Canada, while operating as a Nasdaq-listed issuer in the United States. The company’s reported business and collaboration efforts span North America and Asia, including Hong Kong and the Hong Kong-Shenzhen innovation ecosystem.

Kanada71 %
New Zealand29 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The company faces execution risk because its model depends on converting early-stage bio-engineering work into scalable commercial products. It also has typical biotechnology and agri-tech risks around technical feasibility, regulatory review, partnership dependence, and the challenge of proving a repeatable manufacturing process.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Fermentation scale-up may not translate to commercial output1Commercialization of new ingredients could be delayed2Public company reporting and internal control demands3Partnership and hub initiatives may not close or launch as planned4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Fermentation scale-up may not translate to commercial outputVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Technical milestones in the lab do not always carry over to stable, cost-effective manufacturing.

    Kohdistuu: Precision fermentation and synthetic biology

  2. Commercialization of new ingredients could be delayedVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Customers may require validation, regulatory comfort, and supply reliability before adoption.

    Kohdistuu: B2B biological ingredients

  3. Public company reporting and internal control demandsVaikutus: KeskitasoTodennäköisyys: Korkea

    As a Nasdaq-listed issuer, the company must maintain SEC reporting, controls, and compliance processes.

    Kohdistuu: Corporate governance

  4. Partnership and hub initiatives may not close or launch as plannedVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The Hong Kong collaboration is subject to definitive agreements and customary reviews.

    Kohdistuu: Asia partnerships

Kirjanpito

Harkinnanvaraiset erät
R&D capitalization

Development-stage biotech and fermentation programs often require judgment on when costs should be expensed or capitalized.

Vaikutus: Can materially affect reported operating losses and asset values.

Revenue recognition

Future B2B ingredient or collaboration contracts may involve milestone, delivery, or service-based recognition patterns.

Vaikutus: Can change the timing of revenue and receivables.

Impairment testing

Early-stage platforms and intangibles may need write-downs if commercialization is delayed or assumptions weaken.

Vaikutus: Could create non-cash charges and affect equity.

Fair value estimates

Management may need to estimate the value of development-stage assets, warrants, or other instruments.

Vaikutus: Introduces sensitivity to assumptions and volatility.

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 28.9.2026